NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2024
September 18, 2024 16:15 ET
|
Nanobiotix S.A.
NBTXR3 activé par radiothérapie suivi d’un anti-PD-1 a montré un profil de sécurité favorable, un contrôle de la maladie et une réponse tumorale chez les patients naïfs et résistants aux anti-PD-1,...
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
September 18, 2024 16:15 ET
|
Nanobiotix S.A.
RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune...
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
September 18, 2024 07:50 ET
|
BriaCell Therapeutics Corp.
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT™ to those...
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
September 18, 2024 06:30 ET
|
Purple Biotech Ltd.
High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma...
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
September 18, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck Receives FDA Fast Track Designation for ICT01in Combination with Azacitidine and Venetoclaxin First-Line Acute Myeloid Leukemiafor Patients Unfit for Induction Chemotherapy Treatment ICT01,...
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
September 17, 2024 07:00 ET
|
Omega Therapeutics
Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents...
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
September 17, 2024 06:45 ET
|
BioNTech SE
MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day,...
Telos Corporation, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening New Locations
September 16, 2024 09:21 ET
|
Telos Corporation
ASHBURN, Va., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Telos Corporation (NASDAQ: TLS), an authorized enrollment provider, continues to expand locations to enroll consumers in the TSA PreCheck® program by...
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
September 16, 2024 08:05 ET
|
NextCure
Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism...
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
September 16, 2024 08:00 ET
|
Immutep Limited
Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in...